<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00803088</url>
  </required_header>
  <id_info>
    <org_study_id>08-01</org_study_id>
    <nct_id>NCT00803088</nct_id>
  </id_info>
  <brief_title>Safety of Bronchial Thermoplasty Performed With the Alair® System During Two Treatment Sessions to Treat Severe Asthma</brief_title>
  <acronym>3to2</acronym>
  <official_title>A Multicenter Clinical Trial Evaluating the Safety of Bronchial Thermoplasty Performed With the Alair® System During Two Treatment Sessions to Treat Severe Asthma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asthmatx, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asthmatx, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this multicenter, single-arm, open-label clinical study is to evaluate the
      safety of performing bronchial thermoplasty with the Alair® System during two treatment
      sessions to treat severe asthma.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Current treatment regimen of 3 procedures considered acceptable.
  </why_stopped>
  <start_date>July 2010</start_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Event Profile</measure>
    <time_frame>3 Months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of airways with the Alair System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>The Alair System</intervention_name>
    <description>Treatment of airways with the Alair System</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is an adult between the ages of 18 to 70 years.

          -  Subject is able to read, understand, and sign a written Informed Consent form to
             participate in the Study.

          -  Subject has asthma and is taking maintenance asthma medication that includes:

               1. Inhaled corticosteroid (ICS) at a dosage ≥1000μg beclomethasone per day or
                  equivalent, AND long acting β2-agonist (LABA) at a dosage of ≥100μg per day
                  Salmeterol or equivalent.

               2. Other asthma medications such as leukotriene modifiers, or anti-IgE, are
                  acceptable (Subjects on Xolair® must have been on Xolair for greater than 1
                  year).

               3. Oral corticosteroids (OCS) at a dosage up to, but not greater than, 10mg per day.

          -  Subject has an AQLQ score at Baseline of 6.25 or less.

          -  Subject has a Pre-bronchodilator FEV1 of greater than or equal to 60% of predicted
             after medication stabilization during the Baseline Period.

          -  Subject has a PC20 &lt; 8mg/ml per methacholine inhalation test using standardized
             methods*.

          -  Subject has at least one day of asthma symptoms during the 2 weeks of the Baseline
             Diary Period.

          -  Subject is a non-smoker for 1 year or greater (if former smoker, less than 10 pack
             years total smoking history).

          -  Subject is able to undergo bronchoscopy in the opinion of the Investigator or per
             hospital guidelines.

          -  Subject is willing and able to comply with the Study protocol, attending follow-up
             visits, and requirements for taking and abstaining from medications.

        Exclusion Criteria:

          -  Subject participated in another clinical trial within 6 weeks of the Baseline Period
             involving respiratory intervention that could affect the outcome measures of this
             Study.

          -  Subject requirement during the Baseline Diary period for rescue medication use other
             than for prophylactic use for exercise exceeds an average of:

               1. 8 puffs per day of short-acting bronchodilator, or

               2. 4 puffs per day of long-acting rescue bronchodilator, or

               3. 2 nebulizer treatments per day.

          -  Subject has a post-bronchodilator FEV1 of less than 65% of predicted.

          -  Subject had three or more hospitalizations for exacerbations of asthma in the prior 12
             months.

          -  Subject has a recent history of life-threatening asthma, defined by at least one
             intubation for asthma within the past five years.

          -  Subject had an ICU admission for asthma within the prior 24 months.

          -  Subject had four or more infections of the lower respiratory tract requiring
             antibiotics in the prior 12 months.

          -  Subject had four or more asthma exacerbations requiring oral steroid pulses in the
             prior 12 months.

          -  Subject has a known sensitivity to medications required to perform bronchoscopy (such
             as lidocaine, atropine, benzodiazepines, or other parasympathomimetic agents).

          -  Subject is undergoing immunosuppressant therapy other than steroids (e.g.,
             methotrexate).

          -  Subject uses systemic beta-adrenergic blocking agents.

          -  Subject is an insulin-dependent diabetic.

          -  Subject is pregnant or a nursing mother, or has plans to become pregnant within the
             next 12 months.

          -  Subject has other respiratory diseases including interstitial lung disease, emphysema,
             cystic fibrosis, vocal cord dysfunction, mechanical upper airway obstruction,
             Churg-Strauss syndrome, or active allergic bronchopulmonary aspergillosis (current
             total IgE of &gt;1000 Units/mL with positive specific IgE to aspergillus and evidence of
             central bronchiectasis).

          -  Subject has significant segmental atelectasis, lobar consolidation, significant or
             unstable pulmonary infiltrate, or pneumothorax, confirmed on X-ray.

          -  Subject has chronic sinus disease as defined by five or more episodes of sinusitis in
             past 12 months, or continuous symptoms of sinus infection (purulent discharge) and
             significant change in nasal steroid dosage in last six weeks.

          -  Subject has uncontrolled sleep apnea (sleep apnea not controlled by either dental
             appliances or continuous airway positive pressure (CPAP)).

          -  Subject has uncontrolled gastro-esophageal reflux disease as defined by a significant
             increase in therapy in last six weeks.

          -  Subject has lung cancer or a history of lung cancer.

          -  Subject currently has active cancer or a history of cancer with less than 5 years
             disease free survival time (whether or not there is evidence of local recurrence or
             metastases). Localized basal cell carcinoma (without metastases) of the skin is
             acceptable.

        (Subject with a history of cancer (excluding lung cancer) and a five year or more disease
        free survival time may only be included in this Study by agreement of Sponsor on a case by
        case basis).

          -  Subject has a history of epilepsy.

          -  Subject currently has clinically significant cardiovascular or neurovascular disease,
             including myocardial infarction with congestive heart failure, angina, clinically
             significant cardiac dysrhythmia or conduction defect, cardiomegaly, cardiomyopathy,
             aortic aneurysm, cerebral vascular disease, or stroke.

          -  Subject is on anticoagulant therapy, has a bleeding diathesis, platelet dysfunction,
             or thrombocytopenia with platelet count less than 125,000/mm2 or known coagulopathy
             (INR &gt; 1.5).

          -  Subject has uncontrolled hypertension (&gt;200mm Hg systolic or &gt;100mm Hg diastolic
             pressure).

          -  Subject has an electrical stimulation device such as a pacemaker, defibrillator, or
             deep nerve or deep brain stimulator.

          -  Subject has a psychiatric disorder that in the judgment of the Investigator could
             interfere with provision of Informed Consent, completion of tests, therapy, or
             follow-up visits.

          -  Subject has any other medical condition that in the Investigator's opinion would make
             them inappropriate for Study participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2008</study_first_submitted>
  <study_first_submitted_qc>December 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2008</study_first_posted>
  <last_update_submitted>June 17, 2015</last_update_submitted>
  <last_update_submitted_qc>June 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2015</last_update_posted>
  <responsible_party>
    <name_title>Narinder S Shargill, PhD., Vice President</name_title>
    <organization>Asthmatx, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

